Backers of the company, including Versant Ventures, believe it can make the radiation-emitting drugs more effective against more types of solid tumors while also stopping the therapy from leeching into healthy tissue.
Backers of the company, including Versant Ventures, believe it can make the radiation-emitting drugs more effective against more types of solid tumors while also stopping the therapy from leeching into healthy tissue.
